Loading...
XSHG
603567
Market cap640mUSD
Jul 09, Last price  
4.62CNY
1D
-1.07%
1Q
-32.36%
Jan 2017
-76.62%
IPO
-75.28%
Name

HeiLongJiang ZBD Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603567 chart
P/E
P/S
5.45
EPS
Div Yield, %
3.25%
Shrs. gr., 5y
2.05%
Rev. gr., 5y
-25.18%
Revenues
798m
-70.49%
1,071,278,3651,379,697,2201,414,805,4311,592,911,2482,073,059,8612,391,235,1523,136,522,1052,780,909,8943,291,855,9693,403,747,2804,126,813,8954,214,148,8593,138,186,5532,703,934,333798,063,745
Net income
-1.37b
L
296,063,699389,646,160436,904,116477,300,089585,305,011509,560,908520,872,591462,436,502408,648,869436,285,791332,099,677185,440,375472,740,027438,216,198-1,366,528,671
CFO
322m
+96.03%
104,713,774154,247,334174,683,626386,323,632015,825,550853,192,181367,403,246220,922,861155,178,02500-457,897,889164,308,401322,095,197
Dividend
Aug 20, 20250.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Heilongjiang ZBD Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the entire lifecycle of Traditional Chinese Medicine (TCM), from research and development to manufacturing and sales, exclusively within China. Its extensive product portfolio addresses a wide spectrum of health concerns, including conditions related to cardiovascular and cerebrovascular health, respiratory ailments, orthopedic issues, oncology, digestive disorders, anti-infective treatments, neuropsychiatric conditions, and genitourinary problems, among others. Established in 1996, the company maintains its headquarters in Hulin, China.
IPO date
Apr 24, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT